Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 7

1.

Waldenstrom Macroglobulinemia

Lymphoplasmacytic lymphoma associated with bone marrow involvement and IgM monoclonal gammopathy. [from NCI]

MedGen UID:
6174
Concept ID:
C0024419
Neoplastic Process
2.

Waldenstrom macroglobulinemia

A malignant monoclonal gammopathy characterized by a high level of an IgM monoclonal protein. [from HPO]

MedGen UID:
505816
Concept ID:
CN004877
Finding
3.

Error occurred: cannot get document summary

ID:
447640

4.

Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia (WM) is a malignant B-cell neoplasm characterized by lymphoplasmacytic infiltration of the bone marrow and hypersecretion of monoclonal immunoglobulin M (IgM) protein (review by Vijay and Gertz, 2007). The importance of genetic factors is suggested by the observation of familial clustering of WM (McMaster, 2003). Whereas WM is rare, an asymptomatic elevation of monoclonal IgM protein, termed 'IgM monoclonal gammopathy of undetermined significance' (IgM MGUS) is more common. Patients with IgM MGUS can progress to develop WM, at the rate of 1.5% to 2% per year (Kyle et al., 2003). Genetic Heterogeneity of Waldenstrom Macroglobulinemia One locus for susceptibility to Waldenstrom macroglobulinemia (WM1) maps to chromosome 6p21.3. Another locus (WM2; 610430) maps to chromosome 4q. [from OMIM]

MedGen UID:
320546
Concept ID:
C1835192
Disease or Syndrome
5.

Malignant lymphoma - lymphoplasmacytic

A malignant neoplasm composed of lymphocytes (B-cells), lymphoplasmacytoid cells, and plasma cells. [from NCI]

MedGen UID:
473052
Concept ID:
C0334633
Neoplastic Process
6.

Lymphoplasmacytic Lymphoma

A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein. [from NCI]

MedGen UID:
438046
Concept ID:
C2700641
Neoplastic Process
7.

perifosine

An orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. Perifosine has a lower gastrointestinal toxicity profile than the related agent miltefosine. (NCI04) [from NCI]

MedGen UID:
199998
Concept ID:
C0754570
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...